2020 Clinical Update in Liver Transplantation

Trevor J. Wilke, Bradley A. Fremming, Brittany A. Brown, Nicholas W. Markin, Cale A. Kassel

Research output: Contribution to journalReview articlepeer-review

Abstract

The gold standard treatment of end-stage liver disease continues to be liver transplantation (LT). The challenges of LT require skilled anesthesiologists to anticipate physiologic changes associated with end-stage liver disease and surgical considerations that affect multiple organ systems. While on the waiting list, patients may be placed on new anticoagulation medications that can confound already complex coagulopathy in LT patients. Pain management often is an afterthought for such a complex procedure, but appropriate medications can help control pain while limiting opioid medications. Surgical stress and medications for immunosuppression can affect perioperative glucose management in ways that have implications for patient and graft survival. The coronavirus disease 2019 pandemic in 2020 provided a new challenge for anesthesiologists. The uncertainty of the novel respiratory virus challenged providers beyond just LT patients.

Original languageEnglish (US)
JournalJournal of Cardiothoracic and Vascular Anesthesia
DOIs
StateAccepted/In press - 2021

Keywords

  • COVID-19
  • anesthesiologists
  • anticoagulation
  • coronavirus disease 2019
  • diabetes mellitus
  • end-stage liver disease
  • liver transplantation
  • pain management

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of '2020 Clinical Update in Liver Transplantation'. Together they form a unique fingerprint.

Cite this